Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma.

doi:10.1158/1078-0432.CCR-16-2923

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Sept 2017

Delord Jean-Pierre, Robert Caroline, Nyakas Marta, McArthur Grant A, Kudchakar Ragini, Mahipal Amit, Yamada Yasuhide, Sullivan Ryan, Arance Ana, Kefford Richard F, Carlino Matteo S, Hidalgo Manuel, Gomez-Roca Carlos, Michel Daniela, Seroutou Abdelkader, Aslanis Vassilios, Caponigro Giordano, Stuart Darrin D, Moutouh-de Parseval Laure, Demuth Tim, Dummer Reinhard

Abstract excerpt

Purpose: Encorafenib, a selective BRAF inhibitor (BRAFi), has a pharmacologic profile that is distinct from that of other clinically active BRAFis. We evaluated encorafenib in a phase I study in patients with BRAFi treatment-naïve and pretreated BRAF-mutant melanoma.Experimental Design: The pharmacologic activity of encorafenib was first characterized preclinically. Encorafenib monotherapy was then tested across...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carbamates

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Evaluation, Preclinical

Share to Drug Monitoring

Share to Kaplan-Meier Estimate

Share to Maximum Tolerated Dose

Share to Molecular Targeted Therapy

Share to Sulfonamides

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed

Identifiers

PMID: 28611198
DOI: 10.1158/1078-0432.CCR-16-2923

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma.PMID 28611198Read ↗

Development of encorafenib for BRAF-mutated advanced melanoma.Semantic proximity Read ↗

An evaluation of encorafenib for the treatment of melanoma.Semantic proximity Read ↗

Preclinical discovery and clinical development of encorafenib for the treatment of melanoma.Semantic proximity Read ↗

Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in NRAS-Mutant Melanoma: Results From the Expansion Arm of a Phase Ib, Open-Label Study.Semantic proximity Read ↗

Treatment experience with encorafenib plus binimetinib for BRAF V600-mutant metastatic melanoma: management insights for clinical practice.Semantic proximity Read ↗

A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer.Semantic proximity Read ↗

An overview of binimetinib for the treatment of melanoma.Semantic proximity Read ↗

Efficacy and safety of regorafenib in patients with advanced pretreated melanoma: results of the RegoMel phase II clinical trial.Semantic proximity Read ↗

First-in-human phase I dose-escalation and dose-expansion trial of the selective MEK inhibitor HL-085 in patients with advanced melanoma harboring NRAS mutations.Semantic proximity Read ↗

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.Semantic proximity Read ↗

STARBOARD: encorafenib + binimetinib + pembrolizumab for first-line metastatic/unresectable BRAF V600-mutant melanoma.Semantic proximity Read ↗

In the pipeline: encorafenib and binimetinib in BRAF-mutated melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.